Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/13484
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKershaw, M Hen
dc.contributor.authorTrapani, Joseph Aen
dc.contributor.authorSmyth, Mark Jen
dc.date.accessioned2015-05-16T03:21:01Z
dc.date.available2015-05-16T03:21:01Z
dc.date.issued1995-06-01en
dc.identifier.citationTherapeutic Immunology; 2(3): 173-81en
dc.identifier.govdoc8885135en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/13484en
dc.description.abstractCytotoxic CD8+ T cells and NK cells are involved in the elimination of some viruses, graft rejection, antitumour responses, immunoregulation and some autoimmune diseases. The key role of these cells in each of these immune responses and the therapeutic potential they offer when effectively harnessed, has warranted continued interest in their function. A molecular approach has dominated the recent study of cytotoxic lymphocyte function, allowing the characterization of recognition structures on cytotoxic lymphocytes, the definition of two distinct mechanisms of cytotoxicity and the elucidation of their relevance in vivo. Currently, biological and genetic experimental approaches which exploit the targeted cytolytic activity of lymphocytes are being developed for cancer therapy. A greater understanding of the biology of cytotoxic lymphocytes when adoptively transferred, the development of re-engineered mAbs with tailored properties and the characterization of newly defined endogenous tumour cell antigens, has brought us to the brink of using these cells to greater therapeutic advantage. This review briefly examines ongoing efforts to characterize the mechanism of action of cytotoxic lymphocytes and describes the progression of approaches designed to enhance the anti-tumour activity of these cells.en
dc.language.isoenen
dc.subject.otherAnimalsen
dc.subject.otherAntibodies, Bispecific.therapeutic useen
dc.subject.otherAntibodies, Monoclonal.therapeutic useen
dc.subject.otherAntibodies, Neoplasm.therapeutic useen
dc.subject.otherCytotoxicity, Immunologicen
dc.subject.otherGenetic Engineeringen
dc.subject.otherHumansen
dc.subject.otherImmunotherapy, Adoptiveen
dc.subject.otherNeoplasms.immunology.therapyen
dc.subject.otherT-Lymphocytes, Cytotoxic.immunology.physiologyen
dc.titleCytotoxic lymphocytes: redirecting the cell-mediated immune response for the therapy of cancer.en
dc.typeJournal Articleen
dc.identifier.journaltitleTherapeutic immunologyen
dc.identifier.affiliationCellular Cytotoxicity Laboratory, Austin Research Institute, Austin Hospital, Heidelberg, Victoria, Australiaen
dc.description.pages173-81en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/8885135en
dc.type.austinJournal Articleen
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.